Please assess the completion status of the following clinical trial:

Trial Title: Exparel Interscalene vs Indwelling Catheter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesia (ASA) 1, 2, and 3~* Ages 40-74~* Patients scheduled for total shoulder replacement~Exclusion Criteria:~* ASA 4 and 5~* Pre-existing pain disorder~* Regular consumption of chronic pain medication~* pregnant women~* any medical condition such as a clotting disorder~* anatomic abnormality that precludes use of an indwelling scalene catheter~* Body Mass Index (BMI) \>40~* Patient refusal~* Pre-existing diabetic neuropathy or Hemoglobin A1c \>9~* Failed block

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Single shot Interscalene Nerve Block (Type: EXPERIMENTAL): This group will receive an interscalene nerve block. This will be administered as a single 20mL injection consisting of a mixture of 10mL of Exparel and 10mL of 0.5% bupivacaine hydrochloride.
- Indwelling Interscalene Catheter (Type: ACTIVE_COMPARATOR): This group will receive an indwelling interscalene catheter placed posterior to C5-C6 nerve roots (between the shoulders) and administered 15 mL of 0.5% ropivacaine plain for the block with no superficial cervical block. The On-Q pump will be set at a rate of 4 mL/hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).